RecruitingLung Cancer

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

To learn about the effects of the investigational drug NKTR-255 in combination with the standard drug durvalumab on locally advanced NSCLC when given after CRT.

Sponsor: M.D. Anderson Cancer Center

You may qualify if…

✓ 1. Age 18 years or older
✓ 2. Histologic diagnosis of non-small cell lung cancer
✓ 3. Written consent obtained before initiation of any study-related procedures
✓ 4. Definitive cancer treatment intent
✓ 5. Absence of concurrent malignancies at other sites, except low risk prostate cancer and basal cell of the skin. Participants with prior cancers should not be receiving active cancer treatment within the past 3 months. Cancer survivors who have undergone potentially curative therapy for a prior malignancy who have no evidence of that disease for 1 year and who are deemed at low risk for recurrence are eligible for the study.
✓ 6. Adequate liver (AST, ALT, Alk Phos, and Tbili \<2 fold upper limit) and kidney function (Cr \< 2.5 limit of normal and Cr clearance \>30)
✓ 7. ECOG 0-2

You may not qualify if…

✕ Subjects are to be excluded from the study if any of the following conditions apply:
✕ 1. HIV infection, cellular immune deficiencies, hypogammaglobulinemia or dysgammaglobulinemia, or hereditary or congenital immunodeficiencies
✕ 2. Prior diagnosis of hepatitis B or C (unless anti-hepatitis C therapy has produced a sustained virologic response);
✕ 3. History of clinically significant autoimmune disease, Crohn's disease, ulcerative colitis, or inflammatory disease.
✕ 4. Serious concomitant disorder, including active systemic infection requiring treatment, as judged by the Investigator.
✕ 5. Known or suspected hypersensitivity to any component of the investigational product
✕ 6. Recurrent radiation to the treatment site
✕ 7. Prior major surgery within 4 weeks of enrollment from which the patient has not recovered

Where it's recruiting

Texas

Houston

Source: ClinicalTrials.gov · NCT05632809 · last updated 2026-07-29